Navigation Links
15th ESMO World Congress on Gastrointestinal Cancer
Date:6/21/2013

" The ESMO 15th World Congress on Gastrointestinal Cancer promises to continue the tradition of excellence and stimulate the interest of its participants. We look forward to seeing you in July 2013 in Barcelona for what will be a most important and most memorable scientific meeting."

Mario Dicato, MD and Eric Van Cutsem, MD, PhD - 15th ESMO World GI Congress Co-Chairs

The ESMO 15th World Congress in Gastrointestinal Cancer is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours.

With the focus on personalised therapy, multidisciplinary management and unravelling molecular mechanisms, the congress will update the broad range of experts who participate in the treatment of gastrointestinal cancers, providing a clear overview for treatment.

Highlights on:

  • Adjuvant capecitabine and oxaliplatin (XELOX) for gastric cancer after D2 gastrectomy: final results from the CLASSIC trial
  • REGARD Phase 3, randomized trial of ramucirumab in patients with metastatic gastric or GEJ adenocarcinoma following progression on first-line chemotherapy
  • Updated results of the phase 2 IMPACT trial: Maintenance with MGN1703 vs placebo in patients with advanced colorectal carcincoma (mCRC)
  • Folfoxiri/bevacizumab versus FOLFIRI/bevacizumab as first-line treatment in unresectable metastatic colorectal cancer: results of phase III TRIBE trial by GONO group.
  • FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3)
  • Evaluation of KRAS, NRAS, and BRAF Mutations in PRIME: Panitumumab With FOLFOX4 as First-Line Treatment in Metastatic Colorectal Cancer (mCRC)

Abstracts selected by the Scientific Committee and the Congress Chairs as the Top Abstracts for the ESMO 15th World Congress on Gastrointestinal Cancer ,are available on the Congress website at http://worldgicancer.com/WCGI/WGIC2013/abstracts.asp with other information for the press on or about 3 July 2013.

Other abstracts will be available to subscribers on the Annals of Oncology website at http://annonc.oxfordjournals.org/content/supplemental following the Congress.

The complete scientific agenda is available at http://worldgicancer.com/WCGI/WGIC2013/agenda.asp

Embargo Policy

All abstract details are embargoed until Wednesday, 3 July 2013 at 15:00

Journalists are required to observe embargoes as indicated, thank you!

Conference Chairs:

Mario Dicato, MD, Luxembourg Medical Center, Luxembourg, Luxembourg

Eric Van Cutsem, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

Vice Chair: Josep Tabernero, MD, Vall d'Hebron University Hospital, Barcelona, Spain

Press Registration:

ESMO welcomes media interested in obtaining information and reporting on cancer issues.

Registration is free to bona fide journalists employed by news organizations for the purpose of editorial coverage. Representatives from qualified media outlets must represent editorial staff, not the advertising or marketing staff. Press members may register by forwarding their information and media credentials via email to registration@imedex.com or via fax to +1 (770) 751 7332.

Journalists are required to submit appropriate media credentials as part of their registration application including a photocopy or original business card from an established publication containing your editorial title, a current press identification card, a letter of assignment from the media organization being represented, two bylined medical/health/science articles published within the last six months, or coverage from the previous year's meeting (if applicable), and a copy of the publication.

Media representatives are required to observe and abide by the Media Policy .

Onsite Press Resources:

Press Room

The press room will be located in the International Conventional Center of Barcelona (CCIB), Entrance Hall

Hours:

Wednesday, 3 July 13:00 19:00
Thursday 4- 8:00 18:45
Friday, 5 July 8:00 19:20
Saturday, 6 July 8:30 16:30

Press room facilities include a media-only work area with internet access. Congress materials, scientific highlights, information on Congress representatives, and general information on gastrointestinal cancers will be available.

Interview Room

A room for conducting interviews is located on the M2 level. Press Conferences are not allowed in the Interview room.


'/>"/>

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related medicine news :

1. Worldwide Power Products Expands Its Rental Generator Inventory by $1 Million to Support Its Hurricane Season Response Program
2. Acai Berry Select - Most Exciting Breakthrough in Today's Weight Loss World Now Comes with One Month Extra Supply
3. PrettySkin4Less Launches New Innovative Skin Serums with Active Organic Ingredients to World Wide Consumer Base
4. Pharmacies and Drug Retailers in China Industry Research Report – Now Available from IBISWorld
5. World Leaders in Alzheimer’s Innovation to Discuss Progress, Collaboration at DIA Annual Meeting
6. Sounds Good: Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld
7. Tobacco Growing in China Industry Research Report – Now Available from IBISWorld
8. Veterinary Services in the UK Industry Market Research Report Now Updated by IBISWorld
9. Chopra Center Launches Online Workshop “Manifesting: Living the Life of Your Dreams” – Featuring World-Renowned Teacher and Best-Selling Author Dr. Jean Houston
10. Bergen County NJ Dentist, Dr. Leonid Rubinov, Featured in ‘The Leading Physicians of the World’ 2013
11. Wolfson Children’s Hospital in Jacksonville, FL, Ranks in 5 Specialties among U.S. News & World Report’s 2013-14 Best Children’s Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... ... which specializes in thought leadership , media relations, social media, content marketing ... that will be powered through Act-On, an intuitive marketing automation platform. , Rosica ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... Justice jointly issued a letter to withdraw previous guidance issued by ... gender identity. The guidance issued in May 2016 by the Obama Administration came ...
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial Association (ACPA) ... Meeting. KLS is a longtime supporter of the event. , "We are pleased ... Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a long track ...
(Date:2/23/2017)... Mass. (PRWEB) , ... February 23, 2017 , ... ... as an approved content provider for the National Institute for Health and ... and social care-related organizations in the National Health Service (NHS) to search, order ...
(Date:2/23/2017)... ... , ... ERT, a global data and technology company that ... leading clinical development service provider, has selected ERT’s Trial Oversight suite as its ... to an array of circumstances including the use of multiple data capture modalities ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 24, 2017 Juan ... & Associates PC , a boutique securities firm headquartered ... York City , announces that a class action ... Massachusetts  against Inotek Pharmaceuticals Corporation (NASDAQ: ... the Company,s securities between July 23, 2015 and December 30, ...
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 Report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... estimates and forecasts are provided for the period 2015 through ... markets. Market data and analytics are derived from primary and ...
(Date:2/24/2017)... -- ITL Limited, ( ASX : ITD ), une société ... les excellents résultats semestriels clos le 31 décembre 2016 ... complète « Résultats et mise à jour sur la croissance ... Faits marquants ... en hausse de 104 %) Bénéfice par ...
Breaking Medicine Technology: